<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Cr Bard Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/cr-bard-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISR) IsoRay Begins Prostate Cancer Trial</title>
		<link>http://www.stockbloghub.com/2011/06/22/isr-isoray-begins-prostate-cancer-trial/77129</link>
		<comments>http://www.stockbloghub.com/2011/06/22/isr-isoray-begins-prostate-cancer-trial/77129#comments</comments>
		<pubDate>Wed, 22 Jun 2011 21:14:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[IsoRay Inc]]></category>
		<category><![CDATA[ISR]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TGX]]></category>
		<category><![CDATA[Theragenics Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77129</guid>
		<description><![CDATA[Medical isotope maker IsoRay Inc (ISR) has initiated a new combination therapy study using its Cesium-131 (an isotope) internal radiation therapy (“brachytherapy”) and external beam radiation. The study has been designed to evaluate the effectiveness of combining Cesium-131 brachytherapy with intensity modulated radiation therapy (“IMRT”) in treating intermediate and high risk prostate cancer. Prostate cancer is the second most prevalent cancer (after skin cancer) among American men and the second-leading cause (after lung cancer) of cancer-related death. High level of PSA (a protein produced in the prostate) generally indicate the presence of this disease. More than 30,000 people succumb to prostate cancer annually in the U.S. Based on the available study results, the dual therapy (brachytherapy and external beam radiation) has shown to offer major benefits to prostate cancer patients. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/isr-isoray-begins-prostate-cancer-trial/77129/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMMD) American Medical Systems Starts Implant Registry</title>
		<link>http://www.stockbloghub.com/2011/06/20/ammd-american-medical-systems-starts-implant-registry/76861</link>
		<comments>http://www.stockbloghub.com/2011/06/20/ammd-american-medical-systems-starts-implant-registry/76861#comments</comments>
		<pubDate>Tue, 21 Jun 2011 04:15:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76861</guid>
		<description><![CDATA[Leading pelvic-health devices maker American Medical Systems (AMMD) recently initiated a large-scale global registry of penile prosthetic outcomes. The new registry, dubbed PROPPER (Prospective Registry of Outcomes with Penile Prosthesis for Erectile Restoration), is managed by a crew of eminent urologists looking to better characterize patient satisfaction associated with modern penile prosthetic implants. The multi-year company-sponsored PROPPER registry, essentially the first-of-its-kind, has been designed to better understand the real-world outcomes of penile implant surgery to treat erectile dysfunction (“ED”). The registry is expected to enroll more than 1,000 ED patients recommended for penile prosthesis by their physicians. The research, which will initially engage ten sites, will involve  a prospective measure of patient responses by investigating physicians at regular intervals (over a 1-5 year period) using questionnaires and electronic data collection. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/ammd-american-medical-systems-starts-implant-registry/76861/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMMD) American Medical Systems Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/05/10/ammd-american-medical-systems-analyst-maintains-neutral-rating-on-shares/73777</link>
		<comments>http://www.stockbloghub.com/2011/05/10/ammd-american-medical-systems-analyst-maintains-neutral-rating-on-shares/73777#comments</comments>
		<pubDate>Tue, 10 May 2011 21:01:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73777</guid>
		<description><![CDATA[We maintain our Neutral recommendation on leading pelvic-health devices maker American Medical Systems (AMMD). Its first-quarter fiscal 2011 earnings of 33 cents per share beat the Zacks Consensus Estimate of 30 cents. Both revenues and profit rose roughly 4% year over year on the back of higher sales from the Minnesota-based company’s men’s health and women’s health businesses, assisted by a healthy contribution from its international operation. Sales (of $140.8 million) for the quarter also beat the Zacks Consensus Estimate. American Medical’s men’s health division remained on the growth track supported by the strength at its male continence business. Its benign prostatic hyperplasia (“BPH”) therapy business posted healthy growth in the quarter, led by the GreenLight XPS laser therapy and the next-generation BPH therapy system MoXy Liquid Cooled Fiber. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/ammd-american-medical-systems-analyst-maintains-neutral-rating-on-shares/73777/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien&#8217;s Pipeline Device Cleared</title>
		<link>http://www.stockbloghub.com/2011/04/13/cov-covidiens-pipeline-device-cleared/71004</link>
		<comments>http://www.stockbloghub.com/2011/04/13/cov-covidiens-pipeline-device-cleared/71004#comments</comments>
		<pubDate>Wed, 13 Apr 2011 16:30:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71004</guid>
		<description><![CDATA[Leading healthcare products maker Covidien plc (COV) has secured Premarket Approval (“PMA”) from the U.S. Food and Drug Administration’s (“FDA”) for its Pipeline Embolization Device for treating adults (22 years and above) with large, giant and wide-neck cerebral aneurysms (a brain vascular disorder). The approval follows the unanimous recommendation of the FDA’s advisory panel in March 2011. Covidien obtained the Pipeline Embolization Device following its $2.6 billion acquisition of endovascular devices maker ev3 Inc in July 2010. The device has CE Mark approval in Europe and has been marketed outside the U.S. since July 2009. According to Covidien, it will be available at the existing clinical sites in the U.S. shortly. Cerebral aneurysms is a condition manifested by the dilation of blood vessels in the brain due to weakness in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/cov-covidiens-pipeline-device-cleared/71004/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Unveils New DuraMax Catheter</title>
		<link>http://www.stockbloghub.com/2011/04/10/ango-angiodynamics-unveils-new-duramax-catheter/70970</link>
		<comments>http://www.stockbloghub.com/2011/04/10/ango-angiodynamics-unveils-new-duramax-catheter/70970#comments</comments>
		<pubDate>Mon, 11 Apr 2011 02:57:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70970</guid>
		<description><![CDATA[Therapeutic and diagnostic devices maker AngioDynamics (ANGO) has unveiled its new DuraMax stepped-tip chronic dialysis catheter in the U.S. The Queensbury, New York-based company has also launched the DuraMaxVP (VascPak) component kit designed for outpatient vascular access centers. AngioDynamics has begun shipping the DuraMax catheter, which leverages its proprietary Curved Tip catheter technology. The next generation catheter has been geared to facilitate easier insertion, higher blood flow and dialysis efficiency, thereby improving patient outcomes. Moreover, the catheter’s guidewire lumen, which positions the guidewire in the center of the leading edge of the catheter at the insertion site, significantly improves catheter placement vis-à-vis the existing options. Roughly 30%-50% of dialysis catheters are placed over a guidewire. AngioDynamics is a leading provider of therapeutic and diagnostic devices for treating peripheral vascular and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/10/ango-angiodynamics-unveils-new-duramax-catheter/70970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Catheters Cleared by FDA</title>
		<link>http://www.stockbloghub.com/2011/04/09/stj-st-jude-medical-catheters-cleared-by-fda/70733</link>
		<comments>http://www.stockbloghub.com/2011/04/09/stj-st-jude-medical-catheters-cleared-by-fda/70733#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:21:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70733</guid>
		<description><![CDATA[Medical devices major St. Jude Medical (STJ) has secured the clearance of the U.S. Food and Drug Administration (“FDA”) for its two new irrigated ablation catheters for treating cardiac arrhythmias (irregular heart-beats). The new “Safire BLU” and “Therapy Cool Path” bi-directional ablation catheters possesses a number of new features. Its bi-directional deflection capability allows physicians access difficult-to-reach anatomic locations. Ablation catheters are small tubes that deliver radiofrequency energy (to heat the catheter tip) to the areas of heart muscles causing arrhythmia and create lesions to ablate or interrupt the abnormal electrical signals responsible for irregular heart-beats. The Safire BLU and Therapy Cool Path catheters are designed with irrigated tip, which help reduce risk factors associated with the heat of the radiofrequency energy. The newly approved catheters represent a part of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/stj-st-jude-medical-catheters-cleared-by-fda/70733/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Stock Market News for Dec 15, 2010 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397</link>
		<comments>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397#comments</comments>
		<pubDate>Wed, 15 Dec 2010 21:04:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62397</guid>
		<description><![CDATA[On Tuesday, the markets closed almost flat after a muted view from the Federal Reserve about the economic recovery. However, stocks were helped marginally by the positive report on retail spending. The Dow Jones Industrial Average rose 0.4% to 11,476.54.The Standard &#38; Poor&#8217;s 500 was up 0.1% to 1,241.59.The Nasdaq Composite gained 0.1% to 2,627.72. On the New York Stock Exchange, breadth of the market was negatively biased as for every 17 stocks that fell, 13 stocks ended in the green with a consolidated volume of 957 million shares. The Federal Reserve sketched out a cautious outlook of the economy in its last scheduled meeting of the year. The Fed stated that the economic recovery has not been strong enough to reduce the unemployment rate. The Federal Reserve also said ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien plc Quarterly Earnings Top Expectations &#8211; Profits Skyrocket</title>
		<link>http://www.stockbloghub.com/2010/11/12/cov-covidien-plc-quarterly-earnings-top-expectations-profits-skyrocket/58778</link>
		<comments>http://www.stockbloghub.com/2010/11/12/cov-covidien-plc-quarterly-earnings-top-expectations-profits-skyrocket/58778#comments</comments>
		<pubDate>Fri, 12 Nov 2010 19:46:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58778</guid>
		<description><![CDATA[Ireland-based health care product maker Covidien plc (COV) reported fourth-quarter fiscal 2010 (ended September 24) adjusted earnings per share of 84 cents, exceeding the Zacks Consensus Estimate of 74 cents and the year-ago earnings of 71 cents. For fiscal 2010, adjusted earnings of $3.38 per share outshone the Zacks Consensus Estimate of $3.28 and were above the corresponding year-ago figure of $2.78. Adjusted earnings exclude one-time items such as acquisition and restructuring charges, loss on divestitures and tax-related adjustments. Net income for the quarter was $443 million (or 89 cents a share), representing a staggering eightfold annualized growth. Profits were boosted by higher sales of medical devices. Moreover, the year-ago profit (of $56 million) was hit by hefty tax expenses. For fiscal 2010, net income rocketed 80% year over year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/12/cov-covidien-plc-quarterly-earnings-top-expectations-profits-skyrocket/58778/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien Raises Quarterly Dividend by 11%</title>
		<link>http://www.stockbloghub.com/2010/10/12/cov-covidien-raises-quarterly-dividend-by-11/54554</link>
		<comments>http://www.stockbloghub.com/2010/10/12/cov-covidien-raises-quarterly-dividend-by-11/54554#comments</comments>
		<pubDate>Tue, 12 Oct 2010 14:32:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54554</guid>
		<description><![CDATA[Covidien plc (COV), a leading healthcare products maker, recently enhanced shareholder returns by raising its quarterly dividend by 11% to 20 cents a share from 18 cents. The revised quarterly dividend is payable on Nov 8, 2010, to shareholders of record as on Oct 4, 2010. This represents the Ireland-based company’s second dividend hike over the past 12 months. Covidien’s previous dividend increase was in September 2009, when it raised the quarterly payout by 12.5% to 18 cents a share from 16 cents. Subsequently, its Board of Directors had authorized the repurchase of shares worth up to $1 billion in March 2010. The dividend increase underscores Covidien’s commitment to deliver incremental returns to investors leveraging a solid free cash flow and strong earnings power. The company continues to maintain a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/cov-covidien-raises-quarterly-dividend-by-11/54554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Improves VenaCure Laser Vein Treatment</title>
		<link>http://www.stockbloghub.com/2010/09/16/ango-angiodynamics-improves-venacure-laser-vein-treatment/49900</link>
		<comments>http://www.stockbloghub.com/2010/09/16/ango-angiodynamics-improves-venacure-laser-vein-treatment/49900#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:23:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49900</guid>
		<description><![CDATA[Therapeutic and diagnostic devices maker AngioDynamics Inc. (ANGO) has expanded its VenaCure EVLT laser vein treatment with the launch of a new access kit, which will reduce both procedure time and steps for physicians using VenaCure’s NeverTouch laser fiber to treat varicose veins (abnormally swollen veins), a condition affecting more than 40 million Americans annually. The new access kit, which is equipped with a 0.018 inch long-access wire, trims the number of steps (from 8 to 4) to gain access for the VenaCure EVLT procedure. Besides, the faster procedure time enabled by the kit will lead to improved patient comfort. VenaCure EVLT, which includes DELTA series laser, procedure kits, accessories and a delivery system, offers patients a safe, minimally-invasive and effective option for treating the source of varicose veins while ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/ango-angiodynamics-improves-venacure-laser-vein-treatment/49900/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Company News for September 10, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/09/10/aapl-company-news-for-september-10-2010-corporate-summary/51002</link>
		<comments>http://www.stockbloghub.com/2010/09/10/aapl-company-news-for-september-10-2010-corporate-summary/51002#comments</comments>
		<pubDate>Fri, 10 Sep 2010 15:48:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ADBE]]></category>
		<category><![CDATA[Adobe Systems Inc.]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Barclays plc]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BCS]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Computer Sciences Corporation]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[CSC]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[INTU]]></category>
		<category><![CDATA[Intuit Inc.]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[MCO]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[Moody's Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[National Semiconductor Corporation]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[NSM]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[RBS]]></category>
		<category><![CDATA[Royal Bank of Scotland Group plc]]></category>
		<category><![CDATA[Texas Instruments Inc.]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=51002</guid>
		<description><![CDATA[• National Semiconductor (NYSE:NSM) posted fiscal first quarter results of 36 cents a share, one cent below estimates, on revenues of $412 million, below consensus projections of $415 million. The company CEO noted, &#8220;In the near term, slower growth in our end markets and distribution channel, along with some likely inventory reduction, will mute the seasonal growth that we would normally see in our business during this time of the year,&#8221; cutting the near-term revenue outlook to $415 million from $390 million • Texas Instruments (NYSE:TXN) narrowed guidelines for third quarter sales and earnings • Nokia (NYSE:NOK) replaced its CEO with Microsoft&#8217;s (NASDAQ:MSFT) Stephen Elop • Piper Jaffray (NYSE:PJC) upgraded Moody&#8217;s (NYSE:MCO) to &#8220;overweight&#8221; from &#8220;neutral,&#8221; taking the price target from $29 to $31 • Deutsche Bank (NYSE:DB) initiated coverage of Medtronics (NYSE:MDT) at a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/10/aapl-company-news-for-september-10-2010-corporate-summary/51002/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMMD) American Medical Systems AdVance XP Gets CE Mark</title>
		<link>http://www.stockbloghub.com/2010/08/10/ammd-american-medical-systems-advance-xp-gets-ce-mark/47467</link>
		<comments>http://www.stockbloghub.com/2010/08/10/ammd-american-medical-systems-advance-xp-gets-ce-mark/47467#comments</comments>
		<pubDate>Wed, 11 Aug 2010 01:28:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[SUI]]></category>
		<category><![CDATA[Sun Communities Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47467</guid>
		<description><![CDATA[Leading pelvic-health devices maker American Medical Systems (AMMD) reported that it received the European CE mark for its AdVance XP sling system for the treatment of male stress urinary incontinence (SUI). AdVance XP is the next-generation successor to American Medical’s AdVance (launched in August 2006) minimally invasive sling system for mild SUI. Male SUI, which is characterized by an involuntary loss of urine, affects roughly 5 million men in the U.S. It is a common side effect of prostate cancer and benign prostatic hyperplasia (enlarged prostate) treatments such as prostatectomy (surgical removal of the prostate) and transurethral resection of the prostate (TURP). The condition is often caused by prostate abnormality, urinary tract infection, neurological disorders and aging. Slings are the most commonly used surgical procedure for SUI. It typically consists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/ammd-american-medical-systems-advance-xp-gets-ce-mark/47467/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien Beats The Street by a Nickel</title>
		<link>http://www.stockbloghub.com/2010/07/30/cov-covidien-beats-the-street-by-a-nickel/45401</link>
		<comments>http://www.stockbloghub.com/2010/07/30/cov-covidien-beats-the-street-by-a-nickel/45401#comments</comments>
		<pubDate>Fri, 30 Jul 2010 21:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45401</guid>
		<description><![CDATA[Ireland-based healthcare product maker Covidien plc (COV) reported third-quarter fiscal 2010 results with adjusted (excluding one-time items such as restructuring charges and tax-related adjustments) earnings per share of 85 cents beating the Zacks Consensus Estimate of 80 cents and exceeding the year-ago quarter earnings of 74 cents. Net income from continued operation sailed 29% year-over-year to $352 million (or 70 cents a share), favored by higher medical devices sales and lower research and development expenses. Revenues Net sales edged up 2% year-over-year to $2.56 billion, but missed the Zacks Consensus Estimate of $2.62 billion as incremental revenues from medical devices were marred by the decline in the pharmaceuticals division. Segment Analysis Medical Devices revenues grew 6% year-over-year to $1.54 billion on the back of double-digit revenue expansions across Oximetry and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/30/cov-covidien-beats-the-street-by-a-nickel/45401/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BCR) C.R. Bard Second Quarter 2010 Earnings Beat &#8211; Profit Climbs</title>
		<link>http://www.stockbloghub.com/2010/07/25/bcr-c-r-bard-second-quarter-2010-earnings-beat-profit-climbs/44494</link>
		<comments>http://www.stockbloghub.com/2010/07/25/bcr-c-r-bard-second-quarter-2010-earnings-beat-profit-climbs/44494#comments</comments>
		<pubDate>Mon, 26 Jul 2010 04:47:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44494</guid>
		<description><![CDATA[C. R. Bard (BCR) reported its second quarter results after the closing bell yesterday, with an adjusted (excluding acquisition-related items and write-downs) earnings per share of $1.39 surpassing the Zacks Consensus Estimate of $1.36 and the year-ago earnings of $1.23. Net income surged 11% year over year to $124.6 million (or $1.29 a share), driven by healthy performances across the company’s vascular and surgical specialties businesses. Revenues Revenues leapt 8% year over year to $673.9 million, ahead of the Zacks Consensus Estimate of $671 million, with growth registered across all major business segments. Barring a favorable foreign currency translation, sales increased 7% year over year. Geographically, U.S. sales (up 7%) contributed 69% to Bard’s total revenues while international sales (up 9%) accounted for the balance. Segment Results Revenues from the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/25/bcr-c-r-bard-second-quarter-2010-earnings-beat-profit-climbs/44494/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Files for FDA Pre-Market Approval</title>
		<link>http://www.stockbloghub.com/2010/05/21/evvv-ev3-files-for-fda-pre-market-approval/37947</link>
		<comments>http://www.stockbloghub.com/2010/05/21/evvv-ev3-files-for-fda-pre-market-approval/37947#comments</comments>
		<pubDate>Fri, 21 May 2010 16:25:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37947</guid>
		<description><![CDATA[ev3, Inc. (EVVV) has recently filed the final module of its Pre-market Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for its Pipeline Embolization Device. The company expects the FDA to schedule an advisory panel review of the proposal in late 2010 and the product approval in 2011. The Pipeline Embolization Device is used for treating large, giant and wide-neck aneurysms. The PUFS (Pipeline for Uncoilable or Failed AneurysmS) was a single-arm study of large and giant, wide-neck or fusiform aneurysms that are typically not coilable. The study enrolled and treated 108 patients at 10 centers in the U.S. and Europe. Results were positive with safety and effectiveness endpoints being achieved. The Pipeline Embolization Device is an alternative to present endovascular or surgical treatment options available in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/21/evvv-ev3-files-for-fda-pre-market-approval/37947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Enters Agreement With MEDRAD</title>
		<link>http://www.stockbloghub.com/2010/04/09/evvv-ev3-enters-agreement-with-medrad/33299</link>
		<comments>http://www.stockbloghub.com/2010/04/09/evvv-ev3-enters-agreement-with-medrad/33299#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:29:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33299</guid>
		<description><![CDATA[ev3, Inc. (EVVV) recently entered a new agreement with MEDRAD, Inc. Per the agreement, ev3’s SilverHawk and TurboHawk Plaque Excision Systems will be used in combination with MEDRAD’s Cotavance peripheral drug-eluting balloon angioplasty catheter for use in the DEFINITIVE AR (Anti-Restenosis) European pilot study. The DEFINITIVE AR study evaluates the use of SilverHawk or TurboHawk Plaque Excision Systems along with the Cotavance drug-eluting balloon catheter compared to the use of the Cotavance balloon catheter alone in patients with peripheral arterial disease (PAD). The DEFINITIVE AR study will evaluate up to 125 patients in Europe. ev3 expects to commence the study from the second half of 2010. A global multicenter pivotal trial will start soon after the pilot study gets completed. ev3’s SilverHawk and TurboHawk Plaque Excision Systems are catheter-based technologies. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/evvv-ev3-enters-agreement-with-medrad/33299/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Analyst Downgrades to Neutral</title>
		<link>http://www.stockbloghub.com/2010/03/04/evvv-ev3-analyst-downgrades-to-neutral/29685</link>
		<comments>http://www.stockbloghub.com/2010/03/04/evvv-ev3-analyst-downgrades-to-neutral/29685#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:47:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29685</guid>
		<description><![CDATA[We have recently downgraded ev3 Inc. (EVVV) to Neutral with a target price of $16 based on a P/E of roughly 35.6x our fiscal 2010 EPS estimate of 45 cents. We downgraded the stock based on a downtrend in earnings estimates in the past 30 days. During the 30-day period, six out of ten analysts downgraded their earnings estimates while only three have upgraded theirs for the first quarter of fiscal 2010. For the second quarter, five out of ten analysts have downgraded their earnings estimates while only three have upgraded theirs. For fiscal 2010, seven out of ten analysts downgraded their earnings estimates while only two have upgraded theirs. For fiscal 2011, four have downgraded while only one analyst has upgraded his earnings estimate out of a panel of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/04/evvv-ev3-analyst-downgrades-to-neutral/29685/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Reports Earnings In-Line With Consensus</title>
		<link>http://www.stockbloghub.com/2010/02/24/evvv-ev3-reports-earnings-in-line-with-consensus/28898</link>
		<comments>http://www.stockbloghub.com/2010/02/24/evvv-ev3-reports-earnings-in-line-with-consensus/28898#comments</comments>
		<pubDate>Wed, 24 Feb 2010 18:21:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28898</guid>
		<description><![CDATA[ev3, Inc. (EVVV) recently reported fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were 12 cents, in line with the Zacks Consensus Estimate and higher than the year-ago loss of 2 cents. For fiscal 2009, earnings per share were 40 cents, higher than the loss of 45 cents in the year-ago quarter. Quarterly results Excluding the Merck research collaboration revenues, net sales increased 20% year over year to $126.8 million in the fourth quarter. Excluding a favorable foreign currency translation (FX), net sales increased 16% year over year. Peripheral vascular sales increased 8% year over year to $73.7 million. Growth was led by higher demand for the company’s plaque excision; thrombectomy and embolic protection; and procedural support products. This was partly offset by lower ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/24/evvv-ev3-reports-earnings-in-line-with-consensus/28898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Completes TrailBlazer Support Catheter Recall</title>
		<link>http://www.stockbloghub.com/2010/01/08/evvv-ev3-completes-trailblazer-support-catheter-recall/24448</link>
		<comments>http://www.stockbloghub.com/2010/01/08/evvv-ev3-completes-trailblazer-support-catheter-recall/24448#comments</comments>
		<pubDate>Fri, 08 Jan 2010 20:33:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24448</guid>
		<description><![CDATA[ev3, Inc. (EVVV) recently completed a voluntary Class I recall of its TrailBlazer Support Catheter. The catheter was recalled as a result of the device cracking near its marker band. ev3 received these complaints from physicians during the initial limited market release of the device in the U.S. The company initiated the recall of these devices from November 2009. ev3 recalled roughly 350 individual catheters and at present has the possession of all the affected units. The company has already sent a final closure report regarding the voluntary recall of the affected catheters to the U.S. Food &#38; Drug Administration (FDA). The company also launched a redesigned TrailBlazer Support Catheter globally in December 2009. We think that the recall of these devices will have a minimal impact on the company’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/evvv-ev3-completes-trailblazer-support-catheter-recall/24448/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Launches Two New Products</title>
		<link>http://www.stockbloghub.com/2010/01/05/ango-angiodynamics-launches-two-new-products/24121</link>
		<comments>http://www.stockbloghub.com/2010/01/05/ango-angiodynamics-launches-two-new-products/24121#comments</comments>
		<pubDate>Tue, 05 Jan 2010 18:30:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24121</guid>
		<description><![CDATA[Recently, AngioDynamics (ANGO) expanded its product portfolio by launching two products ? the total abscession nephrostomy drainage catheter and the micro-introducer kits with a new stiffened introducer option. AngioDynamics completed the total abscession family of products by launching the nephrostomy drainage catheter.  The family of products Incorporatedlusive of general drains and a biliary drainage catheter, provides physicians and hospitals a full range of choice from a solitary source. The new drainage catheter is used in percutaneous nephrostomy drainage.  This minimally invasive procedure allows a physician to place the catheter through the skin in the back into the kidney thereby relieving pressure on the organ from a back-up of urine. The launch of a new family of micro-introducer kits by the company is also positive news for physicians. The micro-introducers make ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/ango-angiodynamics-launches-two-new-products/24121/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Beats Consensus Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/28/evvv-ev3-beats-consensus-earnings-estimates/19032</link>
		<comments>http://www.stockbloghub.com/2009/10/28/evvv-ev3-beats-consensus-earnings-estimates/19032#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:30:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19032</guid>
		<description><![CDATA[ev3, Inc. (EVVV), the Zacks Bull of the Day for last Friday (October 23rd), reported third quarter 2009 earnings per share of 17 cents, easily beating the Zacks Consensus Estimate of 2 cents and the year-ago earnings of 4 cents. Sales Net sales in the reported quarter increased 5.4% year over year to $112.8 million. Excluding the research collaboration revenues, net sales increased 12.8% year over year. The company generated research collaboration revenues despite the termination of its agreement with Merck &#38; Co. Inc. (MRK), which ended July 22, 2008. On a geographic basis and excluding the research collaboration revenues, U.S. contributed approximately 61% to total sales and increased 8% year over year. International revenues increased 21% year over year. Growth was seen in all business segments. Peripheral vascular sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/evvv-ev3-beats-consensus-earnings-estimates/19032/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BCR) C.R. Bard Surpasses Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/22/bcr-c-r-bard-surpasses-consensus-estimates/18531</link>
		<comments>http://www.stockbloghub.com/2009/10/22/bcr-c-r-bard-surpasses-consensus-estimates/18531#comments</comments>
		<pubDate>Thu, 22 Oct 2009 22:25:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18531</guid>
		<description><![CDATA[C.R. Bard, Inc. (BCR) yesterday reported strong third quarter fiscal 2009 results after the market close. Earnings per share were $1.31, surpassing the Zacks Consensus Estimate of $1.27 and the year-ago earnings of $1.09. Sales Net sales in the quarter increased 3% year over year to $637.0 million. Excluding an unfavorable foreign currency translation (FX), net sales increased 6% year over year. On a geographic basis, U.S. sales contributed approximately 69.5% of total sales and increased 6% year over year. International sales declined 1% year over year. Growth was witnessed across all major business segments. Vascular sales increased 8% year over year to $173.6 million. Growth was led by strong demand for the disposable electrophysiology [EP], biopsy, peripheral PTA catheters and stent products. This was partly offset by lower surgical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/22/bcr-c-r-bard-surpasses-consensus-estimates/18531/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BCR) C.R. Bard &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/09/04/bcr-c-r-bard-bull-of-the-day/14428</link>
		<comments>http://www.stockbloghub.com/2009/09/04/bcr-c-r-bard-bull-of-the-day/14428#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:39:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14428</guid>
		<description><![CDATA[C.R. Bard (BCR) operates in vascular, urology, oncology and surgical specialty markets. These end-markets should remain insulated from the current economic turmoil. Many of the company&#8217;s products are used in interventional medicine &#8212; life-saving surgical procedures. Future quarters will be met with a headwind from foreign exchange. However, with less than a third of sales outside of the United States, the impact will be less than that for BCR&#8217;s competitors. We retain our Outperform rating on the shares. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/bcr-c-r-bard-bull-of-the-day/14428/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

